AFL vs RNA · P/E 14, rev $4.12B vs rev $22.6M
Aflac Incorporated (AFL) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Aflac Incorporated (AFL) is a insurance - life company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported AFL revenue for 2026-06-30 was $4.12B. Net income was $825.0M. Revenue was down 5.3% from 2026-03-31 to 2026-06-30. AFL currently screens at market cap $60.18B and trailing P/E 13.5.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
AFL currently screens at market cap $60.18B and trailing P/E 13.5. RNA currently screens at market cap $217.5M.
Not investment advice. Open the AFL and RNA stock pages for the full models.
Not investment advice.